Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. The company offers parenteral nutrition vitamins; electrolyte supplements; intravenous iron, trace, electrolytes, and amino acids supplements; antibiotics; acetylcysteine solution for inhalation; medicine for liver diseases; and other special fields. I… Read more
Tibet Weixinkang Medicine Co Ltd - Asset Resilience Ratio
Tibet Weixinkang Medicine Co Ltd (603676) has an Asset Resilience Ratio of 37.55% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Tibet Weixinkang Medicine Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Tibet Weixinkang Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥717.00 Million | 37.55% |
| Total Liquid Assets | CN¥717.00 Million | 37.55% |
Asset Resilience Insights
- Very High Liquidity: Tibet Weixinkang Medicine Co Ltd maintains exceptional liquid asset reserves at 37.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Tibet Weixinkang Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tibet Weixinkang Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Tibet Weixinkang Medicine Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Tibet Weixinkang Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.32% | CN¥803.00 Million | CN¥1.85 Billion | +8.13pp |
| 2023-12-31 | 35.19% | CN¥625.32 Million | CN¥1.78 Billion | +17.95pp |
| 2022-12-31 | 17.24% | CN¥287.00 Million | CN¥1.66 Billion | -14.04pp |
| 2021-12-31 | 31.28% | CN¥467.77 Million | CN¥1.50 Billion | +5.10pp |
| 2020-12-31 | 26.18% | CN¥356.00 Million | CN¥1.36 Billion | -2.18pp |
| 2019-12-31 | 28.35% | CN¥369.90 Million | CN¥1.30 Billion | -9.68pp |
| 2017-12-31 | 38.04% | CN¥386.71 Million | CN¥1.02 Billion | +23.83pp |
| 2016-12-31 | 14.21% | CN¥78.50 Million | CN¥552.36 Million | -- |